21
Nov

Dr. Sara Meyer Joins Sidney Kimmel Cancer Center

The Sidney Kimmel Cancer Center at Jefferson is pleased to announce the appointment of Sara Meyer, PhD, as a new assistant professor in the department of Cancer Biology effective November 1, 2016. Previously, Dr. Meyer was a postdoctoral fellow at Cincinnati Children’s Hospital Medical Center. Dr. Meyer received her PhD in Cell and Molecular Cancer …

16
Feb

Jefferson’s Kimmel Cancer Center Establishes Center to Eliminate Cancer Disparities

PHILADELPHIA—In an effort to reduce and eventually eliminate cancer disparities among adults in the Philadelphia region, the Kimmel Cancer Center at Jefferson has established the Center to Eliminate Cancer Disparities. Edith P. Mitchell, M.D., FACP, a medical oncologist at Thomas Jefferson University Hospital and Clinical Professor of Medicine and Medical Oncology in the Department of …

18
Jan

High Dose Vitamin C for Advanced Pancreatic Cancer

By Josh Goldstein, The Daily Dose @Jefferson A small phase I clinical trial at Jefferson University Hospitals of high-dose, intravenous vitamin C in combination with chemotherapy medications show that this treatment is safe and may have promise for patients with advanced pancreatic cancer. The study published in the open access online journal PLoS ONE tested …

16
Jan

New Clinical Trial: Cabazitaxel with Radiation and Hormone Therapy May Improve Prostate Cancer Survival

Jefferson’s Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients. The single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel …

22
Sep

New Half-Match Bone Marrow Transplant Procedure Featured in Philadelphia Inquirer

Neal Flomenberg, M.D., chair of the Department of Medical Oncology at Jefferson and Dolores Grosso, DNP, co-principal investigator of the study, have developed a way to make stem-cell transplants work, even when only half the immune markers are matched. Featured in the “Check Up” section of The Philadelphia Inquirer, this research has major implications. Half-match transplants would triple …

8
Sep

Half-Match Bone Marrow Transplant Procedure Yields Promising Outcomes for Cancer Patients

Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial conducted at the Kimmel Cancer Center at Jefferson testing its unique, two-step half-match procedure has produced some promising results: the probability of overall survival was 45 percent in all patients after three years …

22
Mar

Jefferson Clinical Trial: Can a Cholesterol Drug Prevent Colon Cancer?

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute (NCI)-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer. Previous laboratory research and population studies have shown that patients taking statins, the class of drugs that lowers cholesterol, had fewer colon polyps, …

21
Feb

Dr. Leonard Gomella co-chairs ASCO GU in Orlando

Dr. Leonard G. Gomella, chair of the Department of Urology and director of Clinical Affairs at the Kimmel Cancer Center at Jefferson, co-chaired the American Society of Clinical Oncology (ASCO) 2011 Genitourinary (GU) Cancers Symposium meeting in Orlando on Feb. 17 though Feb. 19. The “2011 Genitourinary Cancers Symposium: An Evidence-based Multidisciplinary Approach,” was a …

16
Feb

Shifting a paradigm: A molecular approach to staging colorectal cancer

A quantitative, molecular analysis of lymph nodes in patients deemed colorectal cancer-free was found to be an effective predictor of recurrence, according to a study from researchers at the Kimmel Cancer Center at Jefferson and published online Feb 9. in Clinical Cancer Research. Recurrence occurs in about 25 percent of node-negative patients (pN0), suggesting that …

2
Apr

Dr. Leonard G. Gomella Studies the Effect of Dutasteride on the Risk of Prostate Cancer

Dr. Leonard G. Gomella and colleagues conducted a landmark international randomized, double-blind, placebo-controlled, parallel-group multi-center clinical trial to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Over the course of the 4-year study period, dutasteride reduced the risk of …